Our Journey Beyond Sunset Boulevard
The revival of DeltaRex-G (formerly Rexin-G)—the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history—returned active tumor surveillance and a precision-guided “silver bullet” (dnG1 killer gene) to the cancer clinic with “Expanded Access” in 2019. Empowered by US Right-to-...
Gespeichert in:
| Format: | Online |
|---|---|
| Sprache: | Englisch |
| Veröffentlicht: |
IntechOpen
2023
|
| Schlagworte: | |
| Online-Zugang: | ONIX_20231201_9781839694165_2057 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
| Zusammenfassung: | The revival of DeltaRex-G (formerly Rexin-G)—the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history—returned active tumor surveillance and a precision-guided “silver bullet” (dnG1 killer gene) to the cancer clinic with “Expanded Access” in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of “informed consent,” this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors—validating “pathotropic” (disease-seeking) tumor targeting avant la lettre. |
|---|